BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38152053)

  • 1. LNK/
    Wintering A; Hecht A; Meyer J; Wong EB; Hübner J; Abelson S; Feldman K; Kennedy VE; Peretz CAC; French DL; Maguire JA; Jobaliya C; Vasquez MR; Desai S; Dulman R; Nemecek E; Haines H; Hammad M; El Haddad A; Kogan SC; Abdullaev Z; Chehab FF; Tasian SK; Smith CC; Loh ML; Stieglitz E
    Haematologica; 2023 Dec; ():. PubMed ID: 38152053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline bi-allelic
    Arfeuille C; Vial Y; Cadenet M; Caye-Eude A; Fenneteau O; Neven Q; Bonnard AA; Pizzi S; Carpentieri G; Capri Y; Girardi K; Pedace L; Macchiaiolo M; Boudhar K; Khaled MB; Chahla WA; Lutun A; Fahd M; Drunat S; Flex E; Dalle JH; Strullu M; Locatelli F; Tartaglia M; Cavé H
    Haematologica; 2023 Nov; ():. PubMed ID: 37981895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
    Morales CE; Stieglitz E; Kogan SC; Loh ML; Braun BS
    Blood Adv; 2021 Sep; 5(18):3587-3591. PubMed ID: 34464969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JMML genomics and decisions.
    Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
    Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
    Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
    Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
    Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
    Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
    Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
    Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
    Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
    Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.